AstraZeneca's Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients with locally...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - NEWS.MEDICAL.NET - A la Une - 09/Nov 09:58
Novel bladder cancer treatment gains MHRA approval in the UK
Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment of adults with unresectable or metastatic urothelial carcinoma (UC), the most common form of bladder cancer.
Articles similaires
BALVERSA (erdafitinib) tablet, film coated [Janssen Products LP]
nlm.nih.gov - 14/Nov 05:00
Updated Date: Thu, 14 Nov 2024 00:00:00 EST
BALVERSA (erdafitinib) tablet, film coated [Janssen Products LP]
nlm.nih.gov - 14/Nov 05:00
Updated Date: Thu, 14 Nov 2024 00:00:00 EST
Nipocalimab is the First and Only Investigational Therapy Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Adults Living with Moderate-to-Severe Sjögren’s Disease
drugs.com - 11/Nov 02:11
Spring House, PA (November 11, 2024) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has...
LEO Pharma's Anzupgo cream to treat chronic hand eczema receives marketing approval in Switzerland
pharmabiz.com - 16/Nov 09:45
LEO Pharma A/S, a global leader in medical dermatology, announced that Swissmedic, Switzerland's national regulatory agency for approving and...
Oncologist suggests steps to reduce the risk for liver cancer
knowridge.com - 05/Nov 10:59
Liver cancer is the sixth leading cause of cancer death in the U.S. The most common type of liver cancer in adults is hepatocellular carcinoma (HCC),...
Medicinal mbanje products launched in Zimbabwe: help with chronic pain and insomnia…
chronicle.co.zw - 09/Nov 07:20
Nokuthaba Brita Ncube, ncubenokuthababrita@gmail.com In a groundbreaking approach to medical treatment in Zimbabwe, Ivory Medicinal has officially...
Triple Therapy Approach Yields Major Survival Gains in Unresectable Esophageal Cancer
medindia.net - 03:00
The combination of radiation, chemotherapy, and immunotherapy can reduce tumor size and lead to significantly better survival outcomes compared to...
Two studies reflect growing confidence in novel therapy for non-melanoma skin cancer
oncologynews.com.au - 08/Nov 04:37
Non-melanoma skin cancer (NMSC) is the most common type of cancer. NMSC treatment can be painful and cause scarring. Rhenium-SCT® is a non-invasive...
Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
drugs.com - 08/Nov 03:11
November 8, 2024 – Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and...
Les derniers communiqués
-
Aucun élément